US 2003/0125229 A1 · Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium

Abstract

The present invention relates to compositions and methods for preventing the development of epithelial ovarian cancer by administering compounds in an amount capable of increasing TGF-β expression in the ovarian epithelium. HRT and OCP regimens comprising such compositions and methods are disclosed.

Claims1

Dependent claims

A method of formulating a regimen for preventing epithelial ovarian cancer comprising selecting an agent based on its ability to upregulate TGF-β expression in the ovarian epithelium.

Dependencies are inferred from the claim text.

Facts

Application

09/528,963Filed 21 Mar 2000

Published

3 Jul 2003

Term ends

Not estimatedThe source records don’t support an estimate.

Classification4 codes

A61K 31/59
Medicinal preparations containing organic active ingredients: compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
A61K 31/56
Medicinal preparations containing organic active ingredients: compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives…
A61K 31/57
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids: substituted in position 17 beta by a chain…
A61K
Medicines and medical preparations

Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium

Life of this patent

Abstract

Claims1

Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium

Life of this patent

Abstract

Claims1